| Dr Jennifer Vengco Santos, DDS | |
|
3516 Country Club Dr, Glendale, CA 91208-1156 | |
| (818) 957-4403 | |
| Not Available |
| Full Name | Dr Jennifer Vengco Santos |
|---|---|
| Gender | Female |
| Speciality | Dentist - General Practice |
| Location | 3516 Country Club Dr, Glendale, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215079801 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 49403 (California) | Primary |
| Entity Name | Northeast Valley Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629079009 PECOS PAC ID: 3173517323 Enrollment ID: O20040412001067 |
News Archive
According to the U.S. Centers for Disease Control and Prevention, about half of all Americans will have periodontal disease at some point in their lives.
A unique approach to health management was recently announced by FirstSolutions and BeniComp, Inc. The program, FirstPath Advantage, has been developed to close the gap on the health care continuum and dramatically impact employer claims costs.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
Two independent advisory panels to the Food and Drug Administration (FDA) on Friday recommended increasing the cautionary language on the product labels of bone-building drugs taken by more than five million women in the United States. They did not however mention the exact words of the safety warnings and did not recommend limiting use of the drugs to a proposed five years. About 11 percent of women 55 and older take the drugs to prevent bone fractures.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Vengco Santos, DDS 3516 Country Club Dr, Glendale, CA 91208-1156 Ph: (818) 957-4403 | Dr Jennifer Vengco Santos, DDS 3516 Country Club Dr, Glendale, CA 91208-1156 Ph: (818) 957-4403 |
News Archive
According to the U.S. Centers for Disease Control and Prevention, about half of all Americans will have periodontal disease at some point in their lives.
A unique approach to health management was recently announced by FirstSolutions and BeniComp, Inc. The program, FirstPath Advantage, has been developed to close the gap on the health care continuum and dramatically impact employer claims costs.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
Two independent advisory panels to the Food and Drug Administration (FDA) on Friday recommended increasing the cautionary language on the product labels of bone-building drugs taken by more than five million women in the United States. They did not however mention the exact words of the safety warnings and did not recommend limiting use of the drugs to a proposed five years. About 11 percent of women 55 and older take the drugs to prevent bone fractures.
› Verified 5 days ago
Dr. Alenush D Bernardi, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1110 N Brand Blvd Ste 201, Glendale, CA 91202 Phone: 818-244-0215 | |
Dr. Lyla A. Gazarian-boustani, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 230 N Maryland Ave, Suite 206, Glendale, CA 91206 Phone: 818-547-2804 | |
Maricel Guarin Fortin, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1415 E Colorado St, Ste C, Glendale, CA 91205 Phone: 818-545-7270 | |
Dr. Lloyd Thomas Turner, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1111 N Brand Blvd, Suite B, Glendale, CA 91202 Phone: 818-246-5611 | |
Alexander Lalabekyan, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 457 W Colorado St, Suite#201, Glendale, CA 91204 Phone: 818-543-0707 Fax: 818-543-0700 | |
Andre Eliasian, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1249 W Glenoaks Blvd, Glendale, CA 91201 Phone: 818-649-1772 Fax: 818-649-1774 | |
Dr. Greg Tashdjian, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 316 E Broadway, Glendale, CA 91205 Phone: 818-548-7700 |